ALIMENTARY PHARMACOLOGY & THERAPEUTICS, published by Wiley, is a premier scholarly journal in the fields of gastroenterology, hepatology, and pharmacology. With an impressive impact factor and ranking in the top quartile (Q1) of its classifications, the journal is recognized for its rigorous peer-reviewed research and comprehensive reviews, aiming to advance the understanding of therapeutic interventions in gastrointestinal and liver diseases. Since its inception in 1987, it has become an essential resource for researchers, healthcare professionals, and students alike, fostering scientific dialogue and innovation. With a Scopus rank placing it in the 97th percentile for pharmacology and 96th for gastroenterology, it is dedicated to publishing the most significant and impactful findings in the field. ALIMENTARY PHARMACOLOGY & THERAPEUTICS thus plays a vital role in shaping the future of medical treatments and interventions in gastrointestinal health.

The International Journal of Rheumatic Diseases, published by WILEY, serves as a crucial platform for disseminating high-quality research and advancements in the field of rheumatology. With an ISSN of 1756-1841 and an E-ISSN of 1756-185X, this journal has established itself within the academic community since its inception in 2008, and it is set to continue until at least 2024. Positioned in the Q3 category of rheumatology, the journal holds a significant rank of #38 out of 73 in its field according to Scopus, showcasing its growing influence despite the competitive environment. The absence of Open Access reflects a traditional scholarly publishing model, allowing for meticulous peer-review processes to ensure the rigor and reliability of published studies. This journal aims to foster innovative research, critical reviews, and clinical studies, thereby contributing to a deeper understanding of rheumatic diseases and enhancing patient care. The dedicated readership, including researchers, healthcare professionals, and students, will find valuable insights into the latest findings and methodologies relevant to rheumatology in the journal's comprehensive articles.

Intestinal Research is an influential open-access journal dedicated to advancing knowledge in the field of gastroenterology. Published by the Korean Association for the Study of Intestinal Diseases, this journal has been providing valuable insights into intestinal health since its inception in 2003. With an impressive impact factor and a current ranking of Q2 in the gastroenterology category, it is recognized among the top journals in its field, achieving a remarkable 82nd percentile in Scopus rankings. Based in South Korea, the journal's mission is to facilitate research and discussions on intestinal diseases, pathophysiology, innovative treatments, and advancements in care practices. By offering open access, Intestinal Research ensures that critical findings are readily available to researchers, healthcare professionals, and students alike, fostering global collaboration and sharing of knowledge. The journal accepts contributions that reflect the latest developments and foster deep understanding within the intestinal disease research community.

DIGESTION is a prestigious journal dedicated to advancing the field of gastroenterology, published by KARGER, a renowned publisher based in Switzerland. With a rich history dating back to 1896, this journal has continuously evolved and serves as a vital platform for researchers, professionals, and students alike. DIGESTION is recognized for its scholarly contributions, holding an impressive rank of 23 out of 167 in the Scopus database, placing it within the top 14% of gastroenterology journals, as evidenced by its Q2 classification. The journal's commitment to high-quality research is reflected in its wide-ranging scope, addressing various aspects of digestive health, clinical practices, and innovative therapies. Though not an open-access journal, it provides comprehensive access options that ensure the dissemination of crucial research findings to the global community. As we move towards 2024, DIGESTION continues to facilitate dialogue and insights in gastroenterological research, making it an indispensable resource for those in the field.

WORLD JOURNAL OF GASTROENTEROLOGY, published by BAISHIDENG PUBLISHING GROUP INC, stands at the forefront of gastrointestinal research, providing a critical platform for the dissemination of high-quality studies in the field. With an impressive impact factor reflected in its Q1 rankings in both Gastroenterology and Miscellaneous Medicine, this journal is recognized for its rigorous peer-review process and commitment to advancing knowledge and practices related to digestive health. Covering comprehensive scopes from clinical advancements to innovative therapies, the journal serves an essential role for researchers, clinicians, and students, enabling them to stay updated on the latest developments and findings from 1998 through 2024. The open access model facilitates broader accessibility, ensuring that groundbreaking research reaches a global audience. The journal's ranking within the top 15% of Scopus demonstrates its significant contribution to the academic community, making it a valuable resource for advancing the science of gastroenterology.

Crohns & Colitis 360, published by Oxford University Press, is a leading open access journal that has been at the forefront of gastrointestinal research since its launch in 2019. With an E-ISSN of 2631-827X, this journal aims to foster innovation and collaboration within the field of gastroenterology, focusing on diseases such as Crohn's disease and ulcerative colitis. As of 2023, it has earned a commendable Q2 ranking in the gastroenterology category, positioning it among the top 50% of journals in its field, with a Scopus rank of 99 out of 167. Crohns & Colitis 360 not only provides a platform for peer-reviewed research but also seeks to disseminate clinical guidelines, reviews, and groundbreaking studies, making it an essential resource for researchers, healthcare professionals, and students dedicated to advancing the understanding and treatment of inflammatory bowel diseases. Emphasizing accessibility, the journal has been open access since its inception, ensuring that cutting-edge research is readily available to a global audience. This commitment to knowledge sharing significantly enhances its impact and relevance in the ever-evolving landscape of gastroenterology.

DIGESTIVE AND LIVER DISEASE is a prominent journal published by Elsevier Science Inc, dedicated to advancing the field of gastroenterology and hepatology. With an ISSN of 1590-8658 and an E-ISSN of 1878-3562, this journal has established itself as a significant resource within the academic community, especially considering its Q2 ranking in both gastroenterology and hepatology categories as of 2023. Spanning from 2000 to 2024, the journal presents a diverse array of peer-reviewed articles, clinical studies, and review papers that explore the latest advancements and research findings in digestive and liver diseases. The journal's robust impact, reflected in its Scopus rankings—40th out of 167 in gastroenterology and 28th out of 82 in hepatology—highlights its critical role in shaping practices and understanding in these vital areas of medicine. With open access options available, DIGESTIVE AND LIVER DISEASE aims to make high-quality research accessible to a wider audience, thereby encouraging collaboration and innovation. Researchers, healthcare professionals, and students alike will find valuable insights into the complex mechanisms, diagnostics, and therapeutic strategies pertinent to digestive and liver health.

HPB is a premier journal dedicated to advancing the fields of Gastroenterology and Hepatology, published by Elsevier Science Ltd. With an impressive impact factor reflective of its high-quality research output, HPB has earned its place as a Q1 journal in Gastroenterology and Q2 in Hepatology as of 2023. The journal, available in both print and electronic formats (ISSN: 1365-182X; E-ISSN: 1477-2574), serves as a vital platform for multidisciplinary research, encompassing clinical and experimental studies, aimed at improving patient care and outcomes related to liver and biliary diseases. Since its inception in 2000, HPB has published influential articles that have shaped practice and policy in the field. Located in the United Kingdom, at 125 London Wall, London EC2Y 5AS, the journal is poised to continue its mission of fostering innovation and collaboration among researchers, healthcare professionals, and academicians worldwide.

Therapeutic Advances in Gastroenterology, published by SAGE Publications Ltd, is a premier open access journal dedicated to the advancement of knowledge in the field of gastroenterology. Since its inception in 2008 and its transition to open access in 2018, the journal has consistently provided high-quality peer-reviewed research articles, review papers, and clinical studies that address the latest therapeutic advancements and challenges in gastrointestinal medicine. With an impressive impact factor and a 2023 Scopus ranking placing it in the Q1 quartile of gastroenterology journals, it stands as a leading platform for researchers, clinicians, and healthcare professionals. The journal’s commitment to disseminating impactful research has positioned it at the forefront of academic discourse, offering a vital resource for those devoted to improving patient outcomes in digestive health. The United Kingdom-based journal invites submissions that contribute to the understanding and treatment of gastrointestinal disorders, ensuring that cutting-edge findings reach a global audience.

Journal of Crohns & Colitis, published by Oxford University Press, is a premier academic platform dedicated to advancing research in the field of gastroenterology. With an impressive impact factor placing it in the Q1 quartile for both gastroenterology and miscellaneous medicine, this journal stands out as a vital resource for researchers, practitioners, and students interested in inflammatory bowel diseases, particularly Crohn's disease and ulcerative colitis. The journal has successfully converged academic discourse since its inception in 2007, consistently ranking among the top publications in its category, reflecting its reputation and influence within the scientific community. Located in the United Kingdom, the journal offers a platform for disseminating high-quality research and innovative clinical studies, thereby enhancing our understanding and management of gastrointestinal disorders. Researchers are encouraged to submit their findings to contribute to this pivotal dialogue in the field.